RT Journal Article
T1 Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU).
T2 Perfil clínico de los pacientes tratados con evolocumab en unidades de lípidos/medicina interna en España. Estudio observacional (RETOSS-IMU).
A1 Masana, Lluis
A1 Lopez Miranda, Jose
A1 Civeira, Fernando
A1 Reinares, Leonardo
A1 Guijarro, Carlos
A1 Plana, Nuria
A1 Cuenca, Rafael
A1 Sanchez, Demetrio
A1 Hernandez, Jose Luis
A1 Andres, Raimundo
A1 Blanco, Agustin
A1 Villamayor, Santiago
K1 Arteriosclerotic cardiovascular disease
K1 Enfermedad cardiovascular arteriosclerótica
K1 Evolocumab
K1 Familial hypercholesterolaemia
K1 Hipercolesterolemia familiar
K1 LDL-C
K1 Lipid unit/internal medicine
K1 Unidades de lípidos/medicina interna
K1 cLDL
AB To describe the clinical characteristics, the reasons for initiating therapy, and the effects of treatment in the initial phase of evolocumab availability in lipid/internal medicine units in Spain. Retrospective, observational study, based on the medical records of consecutive patients initiating treatment with evolocumab (from February 2016 to July 2017) in 20 internal medicine units in Spain. A review was made of the demographic and clinical characteristics of the patients, the lipid lowering treatment, and the evolution of the lipid profiles between 12weeks pre-initiation and 12±4weeks post-initiation of evolocumab. A total of 136 patients were analysed, of whom 64.0% were men, and the mean age (standard deviation, SD) was 56.6 (11.5) years. The large majority (75%) had familial hypercholesterolaemia (4 homozygous), and 51.0% of them had suffered at least one cardiovascular event. Atherosclerotic cardiovascular disease (ASCVD) was present in 61% of all patients. At initiation of evolocumab, 61.0% of the patients were taking high-intensity statins, and 60.3% were receiving ezetimibe. The mean (and SD) of LDL-C levels at initiation of evolocumab was 169.1 (56.6) mg/dL. The LDL-C was greater than 160mg/dL in 46.4% of patients, and ≥190mg/dL in 26.5%. During the observation period, evolocumab produced significant reductions in LDL-C of 55.7% (P In the lipid/internal medicine units, evolocumab was mainly prescribed in patients with familial hypercholesterolaemia, with or without ASCVD. The initial use of evolocumab was in accordance with the guidelines of the Spanish Society of Arteriosclerosis (SEA) of 2016, with LDL-C levels being well above the recommended thresholds for treatment initiation. Evolocumab treatment in clinical practice reduced LDL-C levels by about 55%, a similar reduction to that reported in clinical trials. Most patients achieved LDL-C goals.
PB Elsevier Espana
YR 2020
FD 2020-02-24
LK http://hdl.handle.net/10668/15404
UL http://hdl.handle.net/10668/15404
LA en
LA es
NO Masana L, López Miranda J, Civeira F, Reinares L, Guijarro C, Plana N, Cuenca R, et al. Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU). Clin Investig Arterioscler. 2020 Sep-Oct;32(5):183-192. English, Spanish.
NO La realización del presente estudio ha sido financiada porAmgen mediante una subvención sin restricciones
DS RISalud
RD Apr 6, 2025